Brain Network Articles & Analysis
7 news found
Neurolief Ltd., a neurotechnology innovator, today announced enrollment of the first patient in its pivotal clinical study evaluating Relivion® DP for the treatment of major depressive disorder (MDD). The Relivion DP is the first non-invasive, multi-channel brain neuromodulation system for at home treatment of neurological and neuropsychiatric disorders. The trial, MOOD, will assess the ...
Neurolief, an Israel-based company pioneering neuromodulation for the treatment of chronic neurological and neuropsychiatric disorders, and NeuroFront, a clinical stage biotech company focusing on innovative neuroscience therapies, jointly announced an exclusive licensing agreement for NeuroFront to develop and commercialize Relivion, non-invasive medical devices for the treatment of migraine and ...
Neurolutions CSO and Founder Dr. Eric Leuthardt has contributed to two recently published studies showing proof that brain-computer interface therapy with the IpsiHand benefits the brain's motor networks and also motor recovery in chronic stroke patients with extended usage. Brain-Computer Interface – The Future of Rehabilitation Brain-computer interface rehabilitation using the IpsiHand ...
Neurolief, an innovator in neurotechnology, announces the company has received Food and Drug Administration (FDA) clearance for its Relivion® system. Relivion® is the first non-invasive multi-channel brain neuromodulation system for at home treatment of acute migraine, a debilitating neurological disease impacting 39 million people and resulting in 1.2 million emergency department visits ...
Neurolief Ltd., a neurotechnology innovator, today announces that it has entered into an exclusive agreement with Sawai Pharmaceutical Co., Ltd. for the development and marketing of Relivion®, a non-invasive digital medical device for migraine and depression, in Japan. Relivion® is a non-invasive brain neuromodulation* device that is placed around the head and delivers unparalleled ...
Neurolief, a neurotechnology innovator, today announces findings of the RIME US pivotal trial that demonstrate the safety and efficacy of the Relivion®, a novel external brain neuromodulation system for self-administered treatment of migraine. The study met all its endpoints with statistical significance. “The results of this study are extremely promising for those seeking an ...
Neurolief, a medical neurotechnology innovator, today announces that the US Food and Drug Administration (FDA) has granted Breakthrough Device designation to the Relivion®DP system, the first non-invasive multi-channel brain neuromodulation technology, for the treatment of major depression. A wearable device, the Relivion®DP system is designed as an adjunctive treatment to pharmaceutical ...